Acorda Therapeutics
15 Skyline Drive
Hawthorne
New York
10532
United States
Tel: 914-347-4300
Fax: 914-347-4560
Website: http://www.acorda.com/
Email: acorda@acorda.com
About Acorda Therapeutics
Acorda Therapeutics is a privately held biotechnology company developing therapies for spinal cord injury (SCI) and related neurological conditions, including multiple sclerosis (MS). The Company's lead product, Fampridine-SR, is in Phase 3 clinical trials for chronic SCI and Phase 2 for MS.Fampridine-SR acts to combat the effects of demyelination in the spinal cord. Myelin is the insulating sheath around nerve processes; when it is damaged due to trauma or disease, electrical impulses from the brain cannot be conducted past the demyelinated area. Fampridine-SR chemically blocks the exposed voltage-gated potassium channels, allowing the impulse from the brain to be conducted more normally past the area of damage. Fampridine is being studied in Phase 3 clinical trials to evaluate its efficacy in reducing spasticity in people with chronic spinal cord injury. Secondary endpoints in the study include evaluating its effect on bladder, bowel, and sexual function. The Company is also conducting a 152 patient, late Phase 2 clinical study in MS to evaluate Fampridine-SR's efficacy in walking speed and muscle strength.
Acorda's technology platform also includes two remyelinating agents in preclinical development for MS. The first is M1, a class of human monoclonal antibodies that have been shown to remyelinate the central nervous system in animal models, and the second is GGF2, a product of the neuregulin 1 gene. Preclinical studies have shown that GGF2 can stimulate the cell growth necessary to protect and regenerate damaged myelin. Additionally, Acorda is developing protein- and stem cell-based technologies for regeneration and repair of the spinal cord and brain.
In 2002, Acorda was the recipient of the National Spinal Cord Injury Association's L. W. Freeman Award for scientific research.
Key Management:
Ron Cohen, M.D., President and CEO Andrew R. Blight, Ph.D., Executive Vice President, Research & Development Mary Fisher, Vice President, Marketing and Strategic Planning Elliott A. Gruskin, Ph.D., Vice President, Research & Development Mitchell Katz, Ph.D., Vice President, Clinical Programs David Lawrence, Vice President, Finance Mark R. E. Pinney, C.F.A., Chief Financial Officer and Director Harold Safferstein, Ph.D., J.D., Vice President, Business Development
Last Updated: 05-09-03
598 articles about Acorda Therapeutics
-
Acorda Therapeutics to Present at the J.P. Morgan SMid Cap Conference
11/24/2010
-
Acorda Therapeutics to Present at the 22nd Annual Piper Jaffray Health Care Conference
11/23/2010
-
Acorda Therapeutics Release: Additional Phase 3 Clinical Trial Data Published in Annals of Neurology Showing Dalfampridine Extended Release Tablets Improved Walking Ability in People with Multiple Sclerosis
11/17/2010
-
Acorda Therapeutics to Present at the Lazard Capital Markets 7th Annual Healthcare Conference
11/9/2010
-
Acorda Therapeutics Posts Profit On MS Walking Drug
11/1/2010
-
Acorda Therapeutics to Host Conference Call to Report Third Quarter 2010 Financial Results on November 1, 2010
10/25/2010
-
Acorda Therapeutics to Present at the 17th Annual NewsMakers in the Biotech Industry Conference
10/18/2010
-
Acorda Therapeutics Announces Data on AMPYRA(R) (dalfampridine) Presented at 26th Congress of European Committee for Treatment and Research in Multiple Sclerosis
10/15/2010
-
Acorda Therapeutics to Present at the Fifth Annual JMP Securities Healthcare Conference
9/20/2010
-
Acorda Therapeutics MS Walking Drug Sales Shine; Loss Narrows
8/3/2010
-
Acorda Therapeutics to Host Conference Call to Report Second Quarter 2010 Financial Results on August 3, 2010
7/27/2010
-
Acorda Therapeutics Announces Receipt of National Institutes of Health (NIH) Grant for Development of GGF2 in Heart Failure
7/20/2010
-
Acorda Therapeutics Announces Douglas Kargman Joins as Vice President of Drug Safety
7/7/2010
-
Acorda Therapeutics President and CEO Ron Cohen Receives New York Biotechnology Association Business Leader of the Year Award
6/8/2010
-
Acorda Therapeutics to Present Data at Joint Consortium of Multiple Sclerosis Centers and Americas Committee on Treatment and Research in Multiple Sclerosis Annual Meetings
6/2/2010
-
Acorda Therapeutics Chief Scientific Officer Andrew R. Blight to Deliver Keynote Lecture at American Spinal Injury Association 36th Annual Scientific Meeting
5/25/2010
-
New York Biotechnology Association to Honor Acorda Therapeutics CEO and VWR International, Inc. with Annual Leadership Awards
5/19/2010
-
Acorda Therapeutics Recognized by National Organization for Rare Disorders for Contribution to Treatment of Multiple Sclerosis
5/18/2010
-
Acorda Therapeutics to Present at the Bank of America Merrill Lynch 2010 Health Care Conference
5/5/2010
-
Acorda Therapeutics Reports First Quarter 2010 Financial Results
4/30/2010